Correlation analysis of HCMV infection and hepatic transaminase after bone marrow hemopoietic stem cell transplantation surgery

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-RCH-08000179

Enrollment

Unknown

Registered

2008-09-04

Start date

2005-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HCMV infection after bone marrow transplantation surgery

Interventions

Infected group:Ganciclovir administration for 8 days before transplantatioin (500mg / day, i.v.)

Ganicclvir for 14days or until antigen negative conversion if there exists HCMV infection (500mg/day, ivgtt, bid).

No infection group:The patients were divided into infection or control group based on the difference of HCMV pp65 in peripheral blood.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria for enrollment of patients were follow-up regularly more than 3 months after transplantation in our hospital and written informed consent.

Exclusion criteria

Exclusion criteria: noneInclusion criteria for enrollment of patients were follow-up regularly more than 3 months after transplantation in our hospital and written informed consent.

Design outcomes

Primary

Measure	Time frame
Onset time of antigen, amounts of pp65 and IE;	—

Secondary

Measure	Time frame
noneAge, sex;	—

Countries

China

Contacts

Public ContactWeihang Ma

maweihang@zju.edu.cn+86 15858224023

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026